TCIM
CRNX icon

TIAA CREF Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

TIAA CREF Investment Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$211K Sell
9,281
-70
-0.7% -$1.72K ﹤0.01% 2872
2018
Q4 		$280K Hold
9,351
– – ﹤0.01% 2791
2018
Q3 		$268K Buy
+9,351
New +$278K ﹤0.01% 2915

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

TIAA CREF Investment Management's CRNX Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 0.75% in Q1 2019, selling an estimated $1.72K and leaving 9,281 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

TIAA CREF Investment Management first reported a position in CRNX in Q3 2018 and has held it in 3 quarters since. The position peaked at $280K in Q4 2018. 62 funds tracked by Wall St. Rank hold CRNX as of Q1 2019.

  • TIAA CREF Investment Management held 9,281 shares of Crinetics Pharmaceuticals worth $211K as of Q1 2019.
  • TIAA CREF Investment Management sold 70 Crinetics Pharmaceuticals shares in Q1 2019, an estimated $1.72K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2872 holding.
  • TIAA CREF Investment Management first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 3 quarters since.
  • TIAA CREF Investment Management's Crinetics Pharmaceuticals position peaked at $280K in Q4 2018.
  • 62 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.